- Home
- ICFI vs IMTX Comparison
ICFI vs IMTX Comparison
Compare ICFI & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICFI | IMTX |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICFI | IMTX |
|---|---|---|
| Price | $97.22 | $10.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $99.25 | $19.25 |
| AVG Volume (30 Days) | 129.5K | ★ 436.5K |
| Earning Date | 02-26-2026 | 11-17-2025 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.30 | N/A |
| Revenue | ★ $1,925,502,000.00 | $99,445,031.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.52 | $19.39 |
| P/E Ratio | $17.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $72.03 | $3.30 |
| 52 Week High | $135.34 | $12.41 |
Technical Indicators
Market Signals| Indicator | ICFI | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.68 | 52.33 |
| Support Level | $90.95 | $8.91 |
| Resistance Level | $94.99 | $10.19 |
| Average True Range (ATR) | 3.30 | 0.51 |
| MACD | 0.82 | -0.02 |
| Stochastic Oscillator | 95.40 | 57.89 |
Price Performance
Historical ComparisonAbout ICFI ICF International Inc.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.